Table 1 Clinical characteristic of patients and controls
Participant characteristics | Total subjects | Active GPA (aGPA) | Inactive GPA (inGPA)a | Disease controls: microscopic polyangiitis (MPA) and eosinophilic GPA (EGPA) | Healthy controls (HC) | Healthy household controls (HHC) |
|---|---|---|---|---|---|---|
84 | 12 | 44 | 13 | 11 | 4 | |
Age (years) | 57.9 (17–73) | 56.1 (42–73) | 58.2 (17–87) | 58.4 (42–76) | 39.4 (23–58) |  |
Gender female | 46.30% | 50% | 47.60% | 38.50% | 81.80% | 50% |
Gender male | 53.70% | 50% | 52.40% | 61.50% | 18.20% | 50% |
Disease duration (months) | 113.3 | 78 | 124.7 | 110.8 | Â | Â |
BVAS WG | 1.1 | 3.5 | 0.7 | 0.2 | Â | Â |
VDI | 2.0 | 2.1 | 1.5 | 3.5 | Â | Â |
DEI | 1.5 | 3.7 | 1.2 | 0.4 | Â | Â |
Steroids | 56.7% | 75% | 47.6% | 69.2% | Â | Â |
Immunosuppressionb | 59.7% | 75% | 57.1% | 53.8% | Â | Â |
CRP (mg/dl) | 7.6 | 14.2 | 7.4 | 2.2 | Â | Â |
ESR (mm/h) | 13.4 | 24.1 | 11 | 10.3 | Â | Â |
eGFR (MDRD) | 87.2 | 83.8 | 87.3 | 90.3 | Â | Â |
Epistaxis | 19.4% | 83.3% | 4.8% | 7.7% | Â | Â |
Mucopurulent discharge | 23.9% | 100% | 9.5% | 0% | Â | Â |
Olfaction | 19.4% | 50% | 7.1% | 30.8% | Â | Â |
Crusting | 37.3% | 75% | 38.1% | 0% | Â | Â |
Inflammation | 24.2% | 100% | 10.5% | 0% | Â | Â |
Bloody discharge | 16.1% | 90.9% | 0% | 0% | Â | Â |
Nasal obstruction | 16.1% | 63.6% | 7.9% | 0% | Â | Â |